Advisor Group Holdings Inc. Raises Stake in AstraZeneca PLC (NASDAQ:AZN)

Advisor Group Holdings Inc. boosted its position in AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 224,050 shares of the company’s stock after buying an additional 22,395 shares during the period. Advisor Group Holdings Inc.’s holdings in AstraZeneca were worth $15,195,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of AZN. Byrne Asset Management LLC boosted its position in AstraZeneca by 55.0% in the 4th quarter. Byrne Asset Management LLC now owns 465 shares of the company’s stock worth $32,000 after purchasing an additional 165 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in AstraZeneca by 1.5% in the 4th quarter. Oppenheimer & Co. Inc. now owns 11,186 shares of the company’s stock worth $758,000 after purchasing an additional 166 shares in the last quarter. Essex Financial Services Inc. boosted its position in AstraZeneca by 3.9% in the 3rd quarter. Essex Financial Services Inc. now owns 4,399 shares of the company’s stock worth $241,000 after purchasing an additional 167 shares in the last quarter. Tealwood Asset Management Inc. boosted its position in AstraZeneca by 0.4% in the 3rd quarter. Tealwood Asset Management Inc. now owns 42,930 shares of the company’s stock worth $2,354,000 after purchasing an additional 170 shares in the last quarter. Finally, Moors & Cabot Inc. boosted its position in AstraZeneca by 1.7% in the 4th quarter. Moors & Cabot Inc. now owns 10,761 shares of the company’s stock worth $730,000 after purchasing an additional 177 shares in the last quarter. Hedge funds and other institutional investors own 16.42% of the company’s stock.

AstraZeneca Trading Down 0.8 %

Shares of AZN stock opened at $71.79 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.90 and a quick ratio of 0.70. The company has a market cap of $222.53 billion, a price-to-earnings ratio of 47.23, a PEG ratio of 1.45 and a beta of 0.52. The stock has a 50 day simple moving average of $73.83 and a 200-day simple moving average of $69.02. AstraZeneca PLC has a 1-year low of $52.65 and a 1-year high of $76.56.

Analyst Ratings Changes

Several research firms have commented on AZN. Morgan Stanley upgraded AstraZeneca from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, April 11th. StockNews.com initiated coverage on AstraZeneca in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $126.00.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.